These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 30213604)
1. Nardilysin: A potential biomarker for the early diagnosis of acute coronary syndrome. Stephenson A; Vaccarezza M Int J Cardiol; 2019 Feb; 277():26. PubMed ID: 30213604 [No Abstract] [Full Text] [Related]
2. Nardilysin: A potential biomarker for the early diagnosis of acute coronary syndrome. Wang W; Ren D; Wang CS; Yao HC Int J Cardiol; 2018 Aug; 265():39. PubMed ID: 29885698 [No Abstract] [Full Text] [Related]
3. Response to Letter of Stephenson et al.: Nardilysin: A potential biomarker for the early diagnosis of acute coronary syndrome. Ohno M; Chen PM; Kimura T; Nishi E Int J Cardiol; 2019 Feb; 277():249. PubMed ID: 30661548 [No Abstract] [Full Text] [Related]
4. Reply: Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome. Chen PM; Ohno M; Kimura T; Nishi E Int J Cardiol; 2018 Aug; 265():236. PubMed ID: 29885690 [No Abstract] [Full Text] [Related]
5. Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome. Chen PM; Ohno M; Hiwasa T; Nishi K; Saijo S; Sakamoto J; Morita Y; Matsuda S; Watanabe S; Kuwabara Y; Ono K; Imai M; Inoue K; Murai T; Inada T; Tanaka M; Kita T; Kimura T; Nishi E Int J Cardiol; 2017 Sep; 243():1-8. PubMed ID: 28747015 [TBL] [Abstract][Full Text] [Related]
6. Suspected acute coronary syndrome in the emergency room: Limited added value of heart type fatty acid binding protein point of care or ELISA tests: The FAME-ER (Fatty Acid binding protein in Myocardial infarction Evaluation in the Emergency Room) study. Bank IE; Dekker MS; Hoes AW; Zuithoff NP; Verheggen PW; de Vrey EA; Wildbergh TX; Timmers L; de Kleijn DP; Glatz JF; Mosterd A Eur Heart J Acute Cardiovasc Care; 2016 Aug; 5(4):364-74. PubMed ID: 25906779 [TBL] [Abstract][Full Text] [Related]
7. [Diagnostic and prognostic biomarkers in acute coronary syndrome]. Kuběna P; Špinar J; Dastych M; Lokaj P; Pařenica J Vnitr Lek; 2018; 63(12):935-944. PubMed ID: 29334742 [TBL] [Abstract][Full Text] [Related]
8. Early biomarkers of acute kidney failure after heart angiography or heart surgery in patients with acute coronary syndrome or acute heart failure. Torregrosa I; Montoliu C; Urios A; Elmlili N; Puchades MJ; Solís MA; Sanjuán R; Blasco ML; Ramos C; Tomás P; Ribes J; Carratalá A; Juan I; Miguel A Nefrologia; 2012; 32(1):44-52. PubMed ID: 22130209 [TBL] [Abstract][Full Text] [Related]
9. Different characteristics of cardiac biomarkers to decide and predict the culprit lesions in patients with suspicious acute coronary syndrome. Kitamura M; Hata N; Takayama T; Hirayama A; Ogawa M; Yamashina A; Mera H; Yoshino H; Nakamura F; Seino Y Heart Vessels; 2016 Jun; 31(6):907-17. PubMed ID: 26081026 [TBL] [Abstract][Full Text] [Related]
10. Midregional pro-A-type natriuretic peptide as part of a dual biomarker strategy for the early rule out of non-ST segment elevation acute coronary syndrome - The WilCop study. Tajsic M; Járai R; Koch J; Stangl K; Wojta J; Dreger H; Huber K Int J Cardiol; 2018 Dec; 273():243-248. PubMed ID: 30282602 [TBL] [Abstract][Full Text] [Related]
11. Complementary, alternative, and putative nontroponin biomarkers of acute coronary syndrome: new resources for future risk assessment calculators. Millard RW; Tranter M Rev Esp Cardiol (Engl Ed); 2014 Apr; 67(4):312-20. PubMed ID: 24774594 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers in acute coronary syndrome and percutaneous coronary intervention. Searle J; Danne O; Müller C; Mockel M Minerva Cardioangiol; 2011 Jun; 59(3):203-23. PubMed ID: 21516070 [TBL] [Abstract][Full Text] [Related]
13. Heart fatty acid binding protein (H-FABP) as a diagnostic biomarker in patients with acute coronary syndrome. Gururajan P; Gurumurthy P; Nayar P; Srinivasa Nageswara Rao G; Babu S; Cherian KM Heart Lung Circ; 2010 Nov; 19(11):660-4. PubMed ID: 20674495 [TBL] [Abstract][Full Text] [Related]
14. Subcellular localization of nardilysin during mouse oocyte maturation. Ma Z; Wang X; Hockman S; Snow EC; Hersh LB Arch Biochem Biophys; 2005 Feb; 434(1):187-94. PubMed ID: 15629122 [TBL] [Abstract][Full Text] [Related]
15. Nardilysin facilitates complex formation between mitochondrial malate dehydrogenase and citrate synthase. Chow KM; Ma Z; Cai J; Pierce WM; Hersh LB Biochim Biophys Acta; 2005 May; 1723(1-3):292-301. PubMed ID: 15809022 [TBL] [Abstract][Full Text] [Related]
16. The use of proteolysis to study the structure of nardilysin. Ma Z; Chow KM; Csuhai E; Hersh LB Arch Biochem Biophys; 2002 May; 401(2):198-204. PubMed ID: 12054470 [TBL] [Abstract][Full Text] [Related]